Biotech Values

[dangerM]

I did not have enough time to look into the data in detail, but sadly, yes: the therapy delivers about what I expect in this non-responder population but there seem to be more sellers than buyers.

I must admit, one thing to consider is the timeline until end of trial/possible accelerated approval ~ 2020 and whether they'll partner or dilute. I hope for the former.